|
|
Post by peppy on Aug 9, 2022 16:58:45 GMT -5
|
|
|
|
Post by peppy on Nov 8, 2022 19:02:31 GMT -5
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Nov 9, 2022 15:43:33 GMT -5
58k current cases of NTM and $3.7B market opportunity by 2030. Dividing $3.7B by 58k patients = $637,931 per patient. I have read so many say this drug will be great for MNKD. Help me out here. Is the Leprosy market expected to grow markedly in the next 8 years, or are there expected to be additional markets (i.e., indications) for this drug? Or, are insurance companies expected to pay $638k/year for these patients? |
|
|
|
Post by tomson1355 on Nov 10, 2022 8:25:54 GMT -5
I think you're off by a factor of ten. I get $63.8k per year.
|
|
|
|
Post by MnkdWASmyRtrmntPlan on Nov 10, 2022 13:02:40 GMT -5
Ah, so I am. I used $37B instead of $3.7B. That makes much more sense.
Thanks, tomson.
|
|
